News Sentiment

VRDN sentiment intelligence

Viridian Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 59 Balanced news tone 62 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 19.74 Week of 10 Jul 2026
Weighted tone 59/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

79/100 classification confidence.

Company focus 56

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

+1.8% over one week, +20.7% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Neutral

Lumvoa’s Unique Profile Leads to Optimism Around Viridian Therapeutics (VRDN)

Market Reaction

Balanced read

68/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 79/100 classification
One-week reaction 1.8% Price digesting
Trend fit Trend inactive 20.7% over four weeks
Fair value 4.0% Near fair-value range
Market Dynamics buy signal

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 21
Neutral 38
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 56
Industry context 6
Sector context 0

Sources

Coverage mix

Publishers
Market source 16
TradingView 8
Stock Titan 8
Simply Wall Street 3
MT Newswires 3
Moomoo 2
AD HOC NEWS 2
Finviz 2

Event Lens

What the news is about

Classified themes
Market update 32
Earnings 13
Regulatory and legal 9
Analyst action 5
Deals and strategy 2
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 62
Investing.com Direct company coverage

Viridian Therapeutic stock rating reiterated at Outperform by William Blair

William Blair has reiterated its Outperform rating on Viridian Therapeutic (NASDAQ:VRDN) following the company's recent discussion of its newly FDA-approved treatment for thyroid eye disease, Lumvoa. The firm expressed increased confidence in Viridian's commercial readiness and t

Tone
Positive 73/100
Event
Analyst action
Published
29 Jun 2026 17:41
Source
Investing.com
The Globe and Mail Direct company coverage

Analysts Are Bullish on These Healthcare Stocks: Viridian Therapeutics (VRDN), Genfleet Therapeutics (Shanghai), Inc. Class H (HK:2595)

Analysts are showing bullish sentiment towards several healthcare stocks, including Viridian Therapeutics (VRDN), Genfleet Therapeutics (Shanghai), Inc. Class H (HK:2595), and Sino Biopharmaceutical (SBMFF). Wedbush analyst Laura Chico maintained a Buy rating on Viridian Therapeu

Tone
Positive 72/100
Event
Analyst action
Published
29 Jun 2026 08:41
Source
The Globe and Mail
BioSpace Direct company coverage

Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment of Thyroid Eye Disease

Viridian Therapeutics has received U.S. FDA approval for Lumvoa™ (veligrotug-vvze) for the treatment of thyroid eye disease (TED), marking the company's first commercial product. Lumvoa is the first approved treatment for TED with data for both active and chronic forms of the dis

Tone
Positive 95/100
Event
Regulatory and legal
Published
29 Jun 2026 07:10
Source
BioSpace
Simply Wall Street Direct company coverage

Why Viridian Therapeutics (VRDN) Is Up 7.6% After FDA Clears First All‑Stage Thyroid Eye Drug

Viridian Therapeutics' stock rose by 7.6% after its drug Lumvoa received FDA approval to treat thyroid eye disease across all stages, making it the first such therapy. This approval shifts Viridian from a development-stage company to a commercial one, with potential for further m

Tone
Positive 77/100
Event
Regulatory and legal
Published
29 Jun 2026 03:39
Source
Simply Wall Street
TradingView Direct company coverage

Price to earnings forward of Viridian Therapeutics, Inc. – NASDAQ:VRDN

This article provides financial information for Viridian Therapeutics, Inc. (NASDAQ:VRDN), specifically focusing on its forward price-to-earnings ratio. It highlights that the market was closed at the time of publication and offers an overview of the company's financial data on T

Tone
Neutral 50/100
Event
Earnings
Published
28 Jun 2026 12:39
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Viridian Therapeutics, Inc. – GETTEX:1S1

The article displays the "Price to earnings forward" for Viridian Therapeutics, Inc. (1S1) traded on Gettex, indicating that the market was closed with no trades recorded for this metric. It also mentions that the data is provided by ICE Data Services and FactSet, and refers to S

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 08:39
Source
TradingView
Stock Titan Direct company coverage

Viridian’s Lumvoa becomes the first FDA-approved TED treatment

Viridian Therapeutics has received FDA approval for Lumvoa (veligrotug-vvze) to treat Thyroid Eye Disease (TED), making it the first approved TED treatment with data for both active and chronic forms of the condition. The approval is supported by positive results from the THRIVE

Tone
Positive 76/100
Event
Earnings
Published
27 Jun 2026 06:39
Source
Stock Titan
Stocktwits Direct company coverage

VRDN Stock Jumps 6% After-Hours As Viridian Wins First FDA Approval

Viridian Therapeutics Inc (VRDN) saw its stock jump 6% after-hours following FDA approval of its drug, Lumvoa, for thyroid eye disease (TED). Lumvoa is the first treatment for TED approved for both active and chronic stages of the condition. The approval is based on strong result

Tone
Positive 92/100
Event
Regulatory and legal
Published
26 Jun 2026 23:11
Source
Stocktwits